PrecisePK
PrecisePK (Healthware Inc.) is a San Diego-based therapeutic drug monitoring software platform providing Bayesian-guided precision dosing recommendations for hospitals, health systems, and academic institutions across 10+ countries, serving 100+ partnerships with 17+ drug models.
- Company typePrivate
- Founded1986
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What PrecisePK does
PrecisePK (legally Healthware Inc., a California corporation) is a San Diego-based software company providing model-informed precision dosing (MIPD) and therapeutic drug monitoring for hospitals, health systems, academic medical centers, and government healthcare facilities. Founded in 1986 and formerly operating as TDMS, the company rebranded to PrecisePK in 2024 around a new web-based platform and currently operates with 11–50 employees. The platform uses Bayesian-guided analytics, two-compartment kinetics models, and population pharmacokinetic (PK) priors combined with patient-specific characteristics (age, weight, renal function, serum concentrations) to generate individualized dosing recommendations for 17+ drugs, including Vancomycin (validated by Turner et al. 2018 as least biased), Busulfan, Methotrexate, Cyclosporine, Infliximab, aminoglycosides, and anticonvulsants. Supporting tools include the AKI Prediction Tool for nephrotoxicity monitoring and EHR integration for clinical workflow embedding. The platform is delivered as both a web application and desktop application, available in five languages, with usage claimed across 10+ countries.
PrecisePK generates revenue primarily through annual or multi-year software licensing subscriptions priced per facility/site, with custom enterprise quotes based on hospital size and needs. The company also offers discounted pricing for academic institutions, students, faculty, and GPO (Group Purchasing Organization) members. Go-to-market combines enterprise field sales (targeting hospitals and healthcare institutions with software demonstrations followed by a 60-day free trial) with inside sales handling inbound inquiries via contact forms. The product-led onboarding path allows self-serve trial registration with sales follow-up within 1–2 business days. Customers include named enterprise healthcare providers such as Sharp HealthCare, Dignity Health, VA, Rady Children's Hospital, UCSD Benioff, Sparrow Health System, and Maryland General Hospital, as well as academic institutions including UCSD Skaggs School of Pharmacy, Stony Brook University, and KGI. The company holds SOC 2 Type 2, ISO/IEC 27001:2022, HIPAA, and GDPR certifications, and is hosted on AWS infrastructure. PrecisePK is privately held and founder/management-owned with no disclosed external institutional investors or venture capital funding.
PrecisePK firmographics
Firmographics- Name
- PrecisePK
- Legal name
- Healthware Inc.
- Website
- https://precisepk.com
- Company type
- Private
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PrecisePK (Healthware Inc.) is a San Diego-based therapeutic drug monitoring software platform providing Bayesian-guided precision dosing recommendations for hospitals, health systems, and academic institutions across 10+ countries, serving 100+ partnerships with 17+ drug models.
- Ownership category
- akta.pro rank
PrecisePK industry classification
Industry- Product category
- Therapeutic Drug Monitoring Software
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)
- akta.pro secondary industry
- Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH)
Keywords
Where PrecisePK is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PrecisePK business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- Software Licensing (Subscription): Annual or multi-year license subscriptions for healthcare facilities. License is per site/facility. One license allows login on any number of computers within the licensed facility. Pricing is customized based on hospital size, specific needs, and associations.
- Academic/Nonprofit Pricing: Special pricing programs for students, faculty, academic professionals, and GPO (Group Purchasing Organization) members.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free Trial - 60-day free trial for qualified institutions |
| Subscription | Annual | Custom Enterprise License - Hospital/facility pricing |
| Subscription | Annual | Academic/Nonprofit Pricing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
PrecisePK product offering
Product offeringCore offering
PrecisePK sells a web-based and desktop therapeutic drug monitoring (TDM) software platform that delivers Bayesian-guided, model-informed precision dosing (MIPD) for hospitals and clinical pharmacists. The platform uses patient-specific characteristics and observed serum concentrations to generate individualized dosing recommendations across a multi-drug model library (vancomycin, aminoglycosides, busulfan, methotrexate, cyclosporine, infliximab, and others), supported by an Acute Kidney Injury (AKI) Prediction Tool and EHR integration.
Product overview
PrecisePK is a unified therapeutic drug monitoring software platform for model-informed precision dosing (MIPD), formerly known as TDMS. The core platform uses Bayesian-guided analytics and machine learning to provide individualized dosage recommendations. The product portfolio includes specialized drug modules for Vancomycin AUC (the most accurate tool per Turner et al 2018), Busulfan, and the new Methotrexate, Cyclosporine, and Infliximab models for transplant and oncology care. An AKI Prediction Tool provides real-time kidney injury monitoring. The system supports 17 drug models including aminoglycosides, anticonvulsants, and immunosuppressants across neonatal, pediatric, and adult populations. Available as both a web-based SaaS application and downloadable desktop app, with multi-language support and EHR integration capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- PreciseRX: Related brand/platform mentioned on the website footer, separate from PrecisePK.
Products and services
- PrecisePK Therapeutic Drug Monitoring Platform
Quantifiable outcome
- Length of hospital stay reduced up to 10 days using therapeutic drug monitoring system
- +4 more outcomes
Companies that use PrecisePK
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
PrecisePK technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration26 records
AI capability5 records
Feature7 records
PrecisePK partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Pacific University OregoncoreStrategic collaboration with Pacific University Oregon to advance precision medicine research and innovation. Announced April 14, 2024, this partnership represents a key academic collaboration to further precision medicine research using PrecisePK's Bayesian dosing technology.
- AWS (Amazon Web Services)coreCloud infrastructure provider for hosting PrecisePK services. All data is hosted on AWS databases located in the United States. AWS provides the underlying cloud security, networking security, and physical resilience for data centers.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
PrecisePK competitors and assessment
Company assessmentDirect peers
- InsightRX: InsightRX is a precision dosing SaaS platform that uses Bayesian PK/PD models to individualize drug dosing for hospitals. It directly competes with PrecisePK in the same clinical use case (vancomycin AUC, aminoglycosides, etc.) and customer base (health system pharmacies).
- DoseMeRx (Tabula Rasa HealthCare): DoseMeRx is a Bayesian precision dosing platform (acquired by Tabula Rasa HealthCare) offering individualized dosing for vancomycin, aminoglycosides, and other drugs. It competes head-to-head with PrecisePK in hospital pharmacy workflows.
- Baysient: Baysient provides Bayesian-guided therapeutic drug monitoring and dosing analytics software for clinicians, with overlap in vancomycin and other key drug models. It is a focused direct competitor in the same precision dosing niche.
Broad incumbents
- Epic Systems: Epic is the dominant hospital EHR vendor and increasingly embeds clinical decision support and dosing calculators. While not a focused TDM vendor, its installed base and integration depth represent a long-term competitive threat to standalone TDM tools like PrecisePK.
- Oracle Health (Cerner): Oracle Health (formerly Cerner) provides hospital EHR systems and increasingly integrates drug dosing and clinical decision support. As a broad incumbent, it competes with PrecisePK for hospital budget and workflow ownership.
- Wolters Kluwer (UpToDate / Sentri7): Wolters Kluwer provides clinical decision support, drug information (Lexicomp/Medispan), and surveillance tools used by hospital pharmacists. It is a broader incumbent competing for the same pharmacy IT budget as PrecisePK.
- First Databank (FDB): FDB supplies drug knowledge bases and clinical decision support that power dosing and screening in many EHRs. It is an adjacent incumbent whose drug content underpins both EHR-embedded dosing and standalone TDM solutions.
Emerging players
- Tabula Rasa HealthCare: Tabula Rasa HealthCare is a pharmacy services and technology company that owns DoseMeRx and offers broader medication safety and pharmacokinetic solutions. It overlaps with PrecisePK through its precision dosing product line.
- RxAnte: RxAnte applies analytics and predictive modeling to medication utilization and adherence for health plans and providers. It is an adjacent player whose predictive analytics approach intersects with PrecisePK's model-informed dosing philosophy.
Others
- GlobalRPH: GlobalRPH is a clinical reference site that independently endorses dosing calculators including PrecisePK's Vancomycin AUC tool. It is an ecosystem/influencer partner rather than a competitor, shaping prescriber awareness of TDM software.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
PrecisePK social profiles
Digital presencePrecisePK compliance and trust
Trust signalCompliance4 records
PrecisePK financial estimates
Financial estimateRevenue estimate
Valuation estimate
PrecisePK leadership team
Management profileNumber of profiles
Profiles1 record
PrecisePK funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PrecisePK M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PrecisePK
What does PrecisePK do?
PrecisePK sells a web-based and desktop therapeutic drug monitoring (TDM) software platform that delivers Bayesian-guided, model-informed precision dosing (MIPD) for hospitals and clinical pharmacists. The platform uses patient-specific characteristics and observed serum concentrations to generate individualized dosing recommendations across a multi-drug model library (vancomycin, aminoglycosides, busulfan, methotrexate, cyclosporine, infliximab, and others), supported by an Acute Kidney Injury (AKI) Prediction Tool and EHR integration.
Is PrecisePK a public or private company?
PrecisePK is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PrecisePK founded?
PrecisePK was founded in 1986. It employs 11 to 50 people.
Where is PrecisePK based?
PrecisePK is headquartered in San Diego, United States, in the North America region.
How does PrecisePK make money?
Two revenue lines are on record. Software Licensing (Subscription) is the primary driver. The others are academic/Nonprofit Pricing.
Who are PrecisePK's main competitors?
Direct peers on record are InsightRX, DoseMeRx (Tabula Rasa HealthCare) and Baysient. Broad incumbents are Epic Systems, Oracle Health (Cerner), Wolters Kluwer (UpToDate / Sentri7) and First Databank (FDB). Emerging players are Tabula Rasa HealthCare and RxAnte. GlobalRPH is listed as an others.
Does PrecisePK have an API?
No public API is recorded for PrecisePK.
What industry is PrecisePK in?
PrecisePK's product category is Therapeutic Drug Monitoring Software. Its primary akta.pro industry code is HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories, with a secondary code of HLACAKAH, Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools. Its NAICS code is 621511 and its SIC code is 2835.